TBT – The Top Papers of 2022

Welcome back Rounds Table Listeners! As we approach the end of 2023, let’s revisit five important research studies from 2022:

1. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (0:00 – 2:56)

2. Tirzepatide Once Weekly for the Treatment of Obesity (2:56 – 6:00)

3. Empagliflozin in Patients with Chronic Kidney Disease (6:00 – 8:35)

4. Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis (8:35 – 11:00)

5. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study (11:00 – 13:38)

Questions? Comments? Feedback? We’d love to hear from you! @roundstable